Clinical Trials Logo

Acute Coronary Syndrome clinical trials

View clinical trials related to Acute Coronary Syndrome.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05323136 Terminated - Clinical trials for ACS - Acute Coronary Syndrome

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics

Start date: April 15, 2022
Phase: Phase 1
Study type: Interventional

The study is a multicenter, Phase 1, open-label, sequential, adaptive, single dose, PK/PD study in subjects with moderate and severe RI and healthy volunteers (HV).

NCT ID: NCT05099926 Terminated - Clinical trials for Acute Coronary Syndrome

The Reducing Exercise Sensitivity With Exposure Training (RESET) Study

RESET
Start date: October 13, 2021
Phase: N/A
Study type: Interventional

This study investigates the feasibility of conducting a home-based reducing exercise sensitivity with exposure training (RESET) intervention among acute coronary syndrome (ACS) survivors. RESET is an at-home, 2 visit intervention that involves psychoeducation, a brief, low-to-moderate intensity walking session (i.e., interoceptive exposure), and interoceptive counseling, and is designed to reduce exercise sensitivity (i.e., fear of exercise sensations) and improve participation in exercise-based secondary-prevention guidelines (cardiac rehabilitation and physical activity). The primary purpose of this pilot study is to test the feasibility, acceptability, and appropriateness of recruiting and administering the RESET intervention in ACS patients.

NCT ID: NCT04822740 Terminated - Type 2 Diabetes Clinical Trials

Evaluation of Continuous Glucose Monitoring in Patients With ACS and Type 2 Diabetes in ICU

EVASION
Start date: December 7, 2022
Phase: N/A
Study type: Interventional

The investigators hypothesize that the use of a continuous glucose monitoring system (CGMS) can reduce glycemic variability assessed by coefficient of variation (CV) during the acute phase of acute coronary syndrome (ACS) in patients with diabetes treated by insulin infusion. The purpose of this project is to assess the impact of the use of CGMS on glycemic variability in diabetic patients with ACS . This is a randomized, multicenter (2 centers), open study. The patients included, as soon as possible, after admission will be randomized before the beginning of insulin therapy with intravenous insulin .

NCT ID: NCT04810806 Terminated - Heart Failure Clinical Trials

Timing of Coronary Angiography in NSTE-ACS With ADHF

EARLY-HF
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The investigators hypothesized that immediate coronary angiography (CAG) within 2 hours after admission can reduce mortality compared to delayed CAG after stabilization of acute decompensated heart failure (ADHF) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) complicated by ADHF. Patients with NSTE-ACS complicated by ADHF will be randomized to immediate CAG (coronary angiography < 2 hours after randomization) or delayed CAG after stablization group by 1:1 fashion. This study is a prospective, non-blinded, randomized trial.

NCT ID: NCT04723186 Terminated - Clinical trials for Acute Coronary Syndrome

MT1002 Phase II Study in ACS Patients With PCI

Start date: December 2, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI. Three doses of MT1002 will be sequentially tested in cohorts of 6 patients each to achieve target ACT.

NCT ID: NCT04625764 Terminated - Clinical trials for Acute Coronary Syndrome

Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery

CyTation
Start date: February 23, 2021
Phase: N/A
Study type: Interventional

The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB, using platelet reactivity to adenosine diphosphate (ADP) as a pharmacodynamics surrogate measure of ticagrelor levels in blood.

NCT ID: NCT04333407 Terminated - COVID-19 Clinical Trials

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.

C-19-ACS
Start date: April 3, 2020
Phase: N/A
Study type: Interventional

The outbreak of a novel coronavirus (SARS-CoV-2) and associated COVID-19 disease in late December 2019 has led to a global pandemic. At the time of writing, there have been 150 000 confirmed cases and 3500 deaths. Apart from the morbidity and mortality directly related to COVID-19 cases, society has had to also cope with complex political and economic repercussions of this disease. At present, and despite pressing need for therapeutic intervention, management of patients with COVID-19 is entirely supportive. Despite the majority of patients experiencing a mild respiratory illness a subgroup, and in particular those with pre-existing cardiovascular disease, will experience severe illness that requires invasive cardiorespiratory support in the intensive care unit. Furthermore, the severity of COVID-19 disease (as well as the likelihood of progressing to severe disease) appears to be in part driven by direct injury to the cardiovascular system. Analysis of data from two recent studies confirms a significantly higher likelihood of acute cardiac injury in patients who have to be admitted to intensive care for the management of COVID-19 disease. The exact type of acute of cardiac injury that COVID-19 patients suffer remains unclear. There is however mounting evidence that heart attack like events are responsible. Tests ordinarily performed to definitely assess for heart attacks will not be possible in very sick COVID-19 patients. Randomising patients to cardioprotective medicines will help us understand the role of the cardiovascular system in COVID-19 disease. It will also help us determine if there is more we can do to treat these patients.

NCT ID: NCT04316481 Terminated - Clinical trials for Acute Coronary Syndrome

IDE-ALERTS Continued Access Study

ALERTS-CAS
Start date: September 22, 2020
Phase: N/A
Study type: Interventional

This Continued Access IDE Study includes a subset of former ALERTS trial (NCT00781118) patients and provides performance data for a refined Guardian implantable medical device (AMSG3-E) with a new battery designed to extend device longevity.

NCT ID: NCT04252703 Terminated - Clinical trials for Cardiovascular Diseases

'MInimalist' or 'MOre Complete' Strategies for Revascularization in Octogenarians

Start date: May 13, 2020
Phase: N/A
Study type: Interventional

Older patients with co-morbidity are increasingly represented in interventional cardiology practice. They have been historically excluded from studies regarding the optimal management of NSTEACS. Though there are associated risks with invasive treatment, such patients likely derive the greatest absolute benefit from PCI. Small, though highly selective, studies suggest a routine invasive strategy may reduce the risk of recurrent myocardial infarction. The study aims to include, as far as possible, an 'all-comers' population of patients aged 80 and above to define the optimum amount of revascularization required to achieve good outcomes and satisfactory symptom relief for this challenging cohort of patients.

NCT ID: NCT04062383 Terminated - Clinical trials for ACS - Acute Coronary Syndrome

Positive Emotions After Acute Coronary Events at Northwestern University

PEACE-NU
Start date: February 24, 2020
Phase: N/A
Study type: Interventional

This study is a single-arm, 12-week trial to test the feasibility of a PP-MI intervention for patients recently admitted following ACS. PP-MI is a novel positive psychology-based health behavior intervention that is adapted for patients hospitalized for ACS. The intervention aims to cultivate positive emotions in this vulnerable population that could provide broad and significant health benefits, and may have distinct-and more powerful-effects than simply attempting to dampen negative emotions. The primary aim is to assess whether the intervention exercises are feasible and linked with immediate boosts in positive affect upon completion. The secondary goal is to provide the research team with greater experience recruiting inpatients with an ACS, successfully completing intervention sessions, and administering psychological and medical assessments by phone.